Nasal Spray Delivery of Insulin and GLP-1 Peptides for Needle-Free Diabetes Treatment
Intranasal delivery of insulin and GLP-1 peptides could eliminate injections for diabetics, offering higher bioavailability and better patient compliance through various formulation strategies.
Quick Facts
What This Study Found
Intranasal delivery of insulin and glucagon-like peptides demonstrates improved therapeutic levels and patient compliance, with drugs transported through epithelial tight junctions via the paracellular route.
Key Numbers
Strategies: polymers, particulate systems, peptide complexation, glucose-responsive systems; paracellular transport through epithelial tight junctions
How They Did This
Narrative review of published literature covering intranasal antidiabetic formulation strategies, absorption mechanisms, challenges, and emerging technologies like glucose-responsive delivery systems.
Why This Research Matters
Needle-free delivery of peptide drugs like insulin and GLP-1 agonists could transform daily diabetes management, improving quality of life and treatment adherence for hundreds of millions of patients worldwide.
The Bigger Picture
The push for needle-free peptide delivery is a major trend in pharmaceutical research. Nasal spray insulin and GLP-1 formulations could make peptide therapies accessible to more patients, especially those who avoid or struggle with injections.
What This Study Doesn't Tell Us
Review with mostly preclinical data. Nasal delivery faces real-world challenges including enzyme degradation, mucociliary clearance, limited nasal cavity volume, and potential irritation. Very few products have reached clinical trials.
Questions This Raises
- ?Can glucose-responsive nasal delivery systems achieve the precision needed for safe insulin dosing?
- ?How do intranasal GLP-1 peptides compare to subcutaneous injection in terms of efficacy and duration?
- ?Will nasal peptide formulations be cost-competitive with existing injection-based treatments?
Trust & Context
- Key Stat:
- Needle-free peptide delivery Intranasal routes could replace painful injections while improving drug absorption and patient compliance for insulin and GLP-1 therapies
- Evidence Grade:
- Not applicable (narrative review). Most evidence comes from preclinical formulation studies with limited clinical trial data.
- Study Age:
- Published in 2021. Nasal peptide delivery research has continued advancing with several formulations now in clinical development.
- Original Title:
- Strategies for the delivery of antidiabetic drugs via intranasal route.
- Published In:
- International journal of pharmaceutics, 608, 121068 (2021)
- Authors:
- Dholakia, Jheel, Prabhakar, Bala, Shende, Pravin(2)
- Database ID:
- RPEP-05343
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Could insulin ever be taken as a nasal spray instead of injection?
Researchers are actively developing nasal insulin formulations using polymers and nanoparticles to protect the drug and enhance absorption. Several approaches show promise in preclinical studies, though commercialization is still ongoing.
What are the main challenges with nasal peptide delivery?
The nasal cavity has limited volume, enzymes that can break down peptides, and a mucus clearance system that quickly removes foreign substances. Formulation strategies like polymer coatings and nanoparticles help overcome these barriers.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05343APA
Dholakia, Jheel; Prabhakar, Bala; Shende, Pravin. (2021). Strategies for the delivery of antidiabetic drugs via intranasal route.. International journal of pharmaceutics, 608, 121068. https://doi.org/10.1016/j.ijpharm.2021.121068
MLA
Dholakia, Jheel, et al. "Strategies for the delivery of antidiabetic drugs via intranasal route.." International journal of pharmaceutics, 2021. https://doi.org/10.1016/j.ijpharm.2021.121068
RethinkPeptides
RethinkPeptides Research Database. "Strategies for the delivery of antidiabetic drugs via intran..." RPEP-05343. Retrieved from https://rethinkpeptides.com/research/dholakia-2021-strategies-for-the-delivery
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.